position: EnglishChannel > Innovation Wire > Article

China's New Drug Benefits to Anemia of Chronic Kidney Disease Patients

Source: International Union for Science and Technology Communication| 2020-04-16 12:39:59| Author: 余昊原

(Beijing,August 2)Roxadustat, a new drug used for treating anemia of chronic kidney disease, has recently been recognized by top international academia. It is expected to lead the revolutionary change in the treatment mode of renal anemia.

The Roxadustat is a "domestic I" new drug that was developed jointly by FibroGen(China) and AstraZeneca(China). It was priority approved and marketed in China, and the Chinese patient can be the first batch to be treated with the new drug in the worldwide. It will bring benefits to 120 million Chinese patients who are suffering from Chronic Kidney Disease. 

Roxadustat can effectively treat and maintain the hemoglobin level for dialysis patients with chronic renal anemia. Before it enters the market, no novel target drug has been developed successfully in the field of renal anemia for nearly 30 years.

Renal anemia is one of the common complications of chronic kidney disease, in which the patient has an unusually low count of red blood cells. 98.2 percent of the dialysis patients have the complication, and the anemia treatment rate of dialysis patients is only 21.3%.

Poor control of the renal anemia will increase the risk of Cardiovascular disease incidence and death among dialysis patients. The symptom can not only affect the patients' physical health, mental health, and social function but also bring a heavy economic burden to their families and even the whole society. 

"It is China firstly debuted the Roxasta capsules in the market. China has become one of the first countries in the world to priority create a mechanism of action drug," said an official from China Food and Drug Administration.

Editor:余昊原

Top News

  • By the end of July, China had increased its daily nucleic acid testing (NAT) capacity to 4.84 million. A total of 4,946 medical institutions, manned by more than 38,000 technicians, are now capable of conducting the test to identify the presence of COVID-19.

Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright © Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com